Quantification of intramuscular fat in patients with late-onset Pompe disease by conventional magnetic resonance imaging for the long-term follow-up of enzyme replacement therapy

• Published in: PloS one 2018-01, Vol.13 (1), p.e0190784-e0190784
• Main Authors: Lollert, André, Stihl, Clemens, Hötker, Andreas M, Mengel, Eugen, König, Jochem, Laudemann, Katharina, Gökce, Seyfullah, Düber, Christoph, Staatz, Gundula
• Format: Article
• Language: English
• Subjects: Biology and Life Sciences; Care and treatment; Correlation; Correlation analysis; Creatine; Creatine kinase; Data analysis; Degeneration; Diagnosis; Disease; Enzyme therapy; Enzymes; Glycogen storage diseases; Image acquisition; Kinases; Magnetic resonance; Magnetic resonance imaging; Medical imaging; Medical research; Medicine and Health Sciences; Metabolism; Methods; Muscle strength; Muscles; Parameters; Patient outcomes; Patients; Pediatrics; Physical Sciences; Psoas muscle; Quantitative analysis; Research and Analysis Methods; Resonance; Signs and symptoms; Spine; Spine (lumbar); Statistical analysis; Supine position; Therapy
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0190784

The objective of this study was to evaluate a quantitative method based on conventional T1-weighted magnetic resonance (MR) imaging to assess fatty muscular degeneration in patients with late-onset Pompe disease and to compare it with semi-quantitative visual evaluation (the Mercuri score). In addition, a long-term retrospective data analysis was performed to evaluate treatment response to enzyme replacement therapy with alglucosidase alfa. MR images of the lumbar spine were acquired in 41 patients diagnosed with late-onset Pompe disease from 2006 through 2015. Two independent readers retrospectively evaluated fatty degeneration of the psoas and paraspinal muscles by applying the Mercuri score. Quantitative semi-automated muscle and fat tissue separation was performed, and inter-observer agreement and correlations with clinical parameters were assessed. Follow-up examinations were performed in 13 patients treated with alglucosidase alfa after a median of 39 months; in 7/13 patients, an additional follow-up examination was completed after a median of 63 months. Inter-observer agreement was high. Measurements derived from the quantitative method correlated well with Medical Research Council scores of muscle strength, with moderate correlations found for the 6-minute walk test, the 4-step stair climb test, and spirometry in the supine position. A significant increase in the MR-derived fat fraction of the psoas muscle was found between baseline and follow-up 1 (P = 0.016), as was a significant decrease in the performance on the 6-minute walk test (P = 0.006) and 4-step stair climb test (P = 0.034), as well as plasma creatine kinase (P = 0.016). No statistically significant difference in clinical or MR-derived parameters was found between follow-up 1 and follow-up 2. Quantification of fatty muscle degeneration using the semi-automated method can provide a more detailed overview of disease progression than semi-quantitative Mercuri scoring. MR-derived data correlated with clinical symptoms and patient exercise capacity. After an initial worsening, the fat fraction of the psoas muscle and performance on the 6-minute walk test stayed constant during long-term follow-up under enzyme replacement therapy.